VA approves (limited) coverage for esketamine
It's been only three months since the FDA approved esketamine, the fast-acting new depression treatment that has many experts excited about its potential, even as others have expressed concern about safety and efficacy.
Now, some veterans may get access to the drug, following a vote by a Department of Veterans Affairs committee.
The committee, however, approved Spravato, as the Johnson & Johnson drug is known, on a “non-formulary” basis, meaning that it will only be available to patients who have not responded to other treatments and who will have to go through an authorization process to get it.
Read more.
Now, some veterans may get access to the drug, following a vote by a Department of Veterans Affairs committee.
The committee, however, approved Spravato, as the Johnson & Johnson drug is known, on a “non-formulary” basis, meaning that it will only be available to patients who have not responded to other treatments and who will have to go through an authorization process to get it.
Read more.
No hay comentarios:
Publicar un comentario